CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Darunavir / cobicistat

Last Updated: April 4, 2014
Result type: Reports
Project Number: SR0378-000
Product Line: Reimbursement Review

Generic Name: Darunavir / cobicistat

Brand Name: TBC

Manufacturer: Janssen Inc.

Therapeutic Area: HIV infection

Indications: HIV infection

Submission Type: Initial

Project Status: Withdrawn